12:00 AM
Oct 30, 2006
 |  BioCentury  |  Product Development

Choking off GERD

XenoPort Inc. hopes that its transported prodrug of baclofen, a generic spasticity drug, will go beyond the symptomatic relief provided by current drugs for gastroesophageal reflux disease by treating the underlying disease pathology. Last week, XNPT reported that XP19986 met the primary endpoint in a Phase IIa trial by reducing the total number of reflux episodes over 12 hours compared with placebo (p=0.005).

GERD is characterized by temporary relaxation of the lower esophageal sphincter, which allows the contents of the patient's stomach to ascend back into the esophagus, causing discomfort and potential damage to the lining of the esophagus. As much as 7% of the population is believed to experience GERD symptoms on a daily basis, and the worldwide market has surpassed $10 billion for products like proton pump inhibitors...

Read the full 641 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >